相关实验视频
Updated: Jul 17, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.8K
通过一种新型双标介导的抗血栓作用,抑制血小板聚合和血栓活性,而不会引起出血
Jinchao Yu1,2, Tianfa Wang1,2, Xiaohan Zhang1,2
1Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Thrombosis and haemostasis
|September 1, 2023
概括
一种新的双目标,PTIP,有效地抑制了血液凝结和血小板聚合. 这种在不引起出血的情况下表现出强大的抗血栓活性,为联合抗血小板和抗凝固疗法提供了潜在的替代品.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 经典的抗凝血剂和抗血小板药具有局限性,包括出血风险和治疗失败.
- 血栓激素在血液凝固中至关重要,而GP IIb/IIIa受体则调解血小板激活.
- 开发针对这两种途径的药物对于有效的抗血栓治疗至关重要.
研究的目的:
- 设计和表征一种新的双抗凝,PTIP.
- 评估PTIP的体外和体内抗血栓疗效.
- 评估PTIP的安全性,特别是它的出血效应.
主要方法:
- 用分子模拟和同质模型来设计PTIP.
- 在体外测试中评估了PTIP对凝血和血小板聚合的影响.
- 在体内模型 (肺血栓塞栓症,铁化物损伤,动脉静脉绕道) 评估了抗血栓活性和出血风险.
主要成果:
- 在体外,PTIP有效地抑制了由血介导的凝血和ADP诱导的血小板聚合.
- PTIP显示了剂量依赖的抗凝剂作用和抑制了血小板聚合in vivo.
- 在各种模型中,PTIP显著降低了血栓形成,并且在不引起出血的情况下预防了深静脉血栓形成.
结论:
- PTIP是一种新型抗血栓剂,其向纤维素生成和血小板激活.
- 在静脉和动脉血栓形成模型中,PTIP显示出有效性.
- PTIP可以作为一种单一的药物来取代结合的抗血小板和抗凝药治疗血栓性疾病.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
560
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
560
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
749
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:22Formation of the Platelet Plug
6.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.6K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
213
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
213